Luca Arecco/X
May 18, 2025, 09:11
Luca Arecco Shares ESMO Panel Consensus on Extended Endocrine Therapy in HR+ HER2- Breast Cancer
Luca Arecco, Clinical Research Fellow at ESMO, posted on X:
“ESMO Breast consensus.
Question: What is your recommended #extended adjuvant endocrine therapy for a woman aged 37-y with luminal B-like (G3 high Ki67 / RS) HR+ HER2- BC?
More than half of panelists would give extended OFS with higher nodal involvement (>5 N+).”
More posts featuring ESMOBreast25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41
Sep 2, 2025, 16:27
Sep 2, 2025, 16:24
Sep 2, 2025, 16:18